INCY

Business Context and Reporting Period

This Form 10-K covers Incyte Corporation for the fiscal year ended December 31, 2003. Incyte is a biotechnology company transitioning from a provider of genomic information products to a focused developer of novel small-molecule drugs for HIV, inflammatory disorders, cancer, and diabetes. The company's most advanced product candidate, Reverset (an HIV treatment), is in Phase II clinical trials. In February 2004, the company announced a major restructuring to close its Palo Alto headquarters and discontinue most information product lines, shifting its primary focus to drug discovery and development.

Key Financial Metrics

Material Changes Versus Prior Period

• Revenue Decline: Revenues decreased 54% to $47.1 million, driven by a softening market for genomic information products and reduced research spending by pharmaceutical customers. Information products accounted for 100% of 2003 revenue.
• Increased Net Loss: Net loss widened to $166.5 million from $136.9 million. This was primarily due to the revenue decline, a $34.0 million charge for purchased in-process research and development (IPRD), and $18.0 million in long-term investment impairments.
• Acquisition and Licensing: The company recorded $27.7 million in IPRD charges for the acquisition of Maxia Pharmaceuticals and $6.3 million for a collaborative license agreement with Pharmasset regarding Reverset.
• Restructuring Charges: The company recorded $11.5 million in restructuring charges in Q4 2003 related to headcount reductions and asset write-downs for its genomic information business.
• Cash Position: Cash and marketable securities decreased by $135.2 million to $293.8 million, reflecting operating losses and capital expenditures, though the company maintains a positive working capital position.

Guidance, Outlook, and Risks

• Restructuring Outlook: Following the February 2004 announcement, Incyte estimates up to $47 million in restructuring charges in 2004, with a cash impact of up to $23 million. The company expects to reduce annual operating expenses by up to $50 million.
• R&D Guidance: Total R&D expenses for 2004 are expected to range from $91 million to $95 million, with approximately $73 million dedicated to drug discovery and development.
• Clinical Pipeline: The company plans to initiate a Phase II trial for Reverset in treatment-experienced HIV patients in the first half of 2004. A lead CCR2 antagonist candidate is expected to enter Phase I trials in the first half of 2004.
• Liquidity and Capital Needs: Incyte expects to incur losses for several years. In February and March 2004, the company issued $250 million in new convertible subordinated notes to fund operations. Management believes current cash and new proceeds will satisfy capital needs for at least the next twelve months.
• Legal Contingencies:
  • Invitrogen: Patent infringement litigation is stayed pending an appeal; outcome is uncertain.
  • Iconix Pharmaceuticals: Arbitration is pending regarding alleged contract payments of $28.25 million. Incyte disputes the obligation.
• Risks: Significant risks include the failure of drug candidates in clinical trials, inability to obtain regulatory approval, dependence on third-party collaborators, and the need for additional capital if drug development timelines extend.

Investor Verification Checklist

• Verify the status and results of the Reverset Phase II clinical trials, particularly regarding efficacy in treatment-experienced patients.
• Confirm the actual cash impact and timing of the $47 million restructuring charges announced for 2004.
• Monitor the outcome of the arbitration with Iconix Pharmaceuticals regarding the $28.25 million claim.
• Assess the progress of the CCR2 receptor antagonist program entering clinical trials in 2004.
• Review the company's cash burn rate against the $293.8 million cash balance and the $250 million in new debt issued in early 2004.
• Track the status of the Invitrogen patent litigation stay and potential damages.